Spondyloarthritis & psoriatic arthritis
Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
Authors' conclusion
Tofacitinib treatment resulted in improvements in enthesitis in patients with PsA, regardless of baseline location or severity.
Study context
- Population
- Patients with active psoriatic arthritis (PsA), by baseline enthesitis location and severity (Leeds Enthesitis Index (LEI), SPARCC)
- Participants
- 710 patients2 phase 3 studies
- Comparison
- Tofacitinib 5 or 10 mg twice daily to M6 vs placebo to M3
- Outcome
- Change from baseline in LEI and SPARCC across baseline enthesitis locations/severities
- Follow-up
- Up to M3
Methodological detailspooled data, placebo-controlled
- Pooled data
- Placebo-controlled
Pooled result
As reported in the abstract
up to M3
Change in LEI, tofacitinib vs placebo (greater with tofacitinib)
−2.0-0.4 vs -0.9-0.4
Change in SPARCC, tofacitinib vs placebo (greater with tofacitinib)
−3.5-0.2 vs −1.5-1.1
Further pooled results
Relapse of enthesitis resolved by M1/M3 (baseline LEI > 0 or SPARCC > 0) · M6
- Patients with relapse
- ≤ 40%
De novo enthesitis (baseline LEI = 0 and SPARCC = 0) · M6
- Patients with de novo enthesitis
- < 14%
Enthesitis at M6 by baseline severity
- More common with greater baseline enthesitis severity
Low disease activity (LDA)/remission
- Rates generally increased with tofacitinib over time
Association of baseline enthesitis with PRO change
- Baseline LEI location significantly associated with change in arthritis pain score
- Baseline SPARCC severity significantly associated with change in FACIT-F total and arthritis pain scores
Original publication
Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Ther. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →